Opsidio, LLC, a US-based clinical stage biotechnology company, announced on Wednesday that it has dosed its first subject in the Phase 2a clinical trial of OpSCF, the company's pioneering monoclonal antibody against stem cell factor, in subjects suffering from moderate to severe atopic dermatitis.
The company is collaborating with AbbVie for the development of OpSCF.
The study, a randomised, double-blind, placebo-controlled, Phase 2a study, is to assess the efficacy and safety of OpSCF in the treatment of adults with moderate to severe atopic dermatitis. The primary endpoint is the percent change in the Eczema Area and Severity Index (EASI) score from baseline, at week 16, while the secondary endpoint comprises safety and tolerability and improvement in pruritus, body surface area, and quality of life.
Indivior updates on Aelis Farma's Phase 2B study of AEF0117 for Cannabis Use Disorder
Vesper Bio announces positive Phase I results for FTD treatment
Empower Pharmacy names new president
Innovent's IBI363 receives US FDA Fast Track Designation
Valneva and Pfizer report positive Phase 2 booster results for Lyme disease vaccine
Grit Biotechnology's GT201 receives US FDA IND approval
Cereno Scientific doses first patient in Expanded Access Program for PAH
Medicilon USA begins operations at second R&D centre in Massachusetts
CS Genetics names new chief operating officer and chief scientific officer
Expanse Medical names new chief executive officer and FlowPhysix board member